These include such the c-Jun N-terminal kinases (JNK) inhibitor SR3306, investigated for dopaminergic neuron protection in animal models of Parkinson’s disease (PD) [50] and the leucine-rich repeat kinase 2 (LRRK2) inhibitor GNE-7915, which along with its derivatives showed promising pharmacokinetic and safety profiles in rodent and non-human primate models for potential application of LRRK2 inhibition in PD [51]. The gene discussed is LRRK2; the disease is Parkinson disease.